BioMarin Pharmaceutical Inc. $BMRN is Eagle Health Investments LP's 9th Largest Position

Eagle Health Investments LP lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 366,812 shares of the biotechnology company's stock after selling 15,800 shares during the quarter. BioMarin Pharmaceutical makes up about 5.0% of Eagle Health Investments LP's holdings, making the stock its 9th largest position. Eagle Health Investments LP owned about 0.19% of BioMarin Pharmaceutical worth $20,164,000 at the end of the most recent quarter.

• Can BioMarin Stock Live Up to Wall Street’s High Expectations?

Several other institutional investors and hedge funds have also made changes to their positions in BMRN. Swiss National Bank increased its holdings in BioMarin Pharmaceutical by 8.0% during the 2nd quarter. Swiss National Bank now owns 580,500 shares of the biotechnology company's stock valued at $31,910,000 after acquiring an additional 43,000 shares in the last quarter. Prudential PLC lifted its holdings in shares of BioMarin Pharmaceutical by 378.8% in the second quarter. Prudential PLC now owns 30,480 shares of the biotechnology company's stock valued at $1,675,000 after purchasing an additional 24,114 shares in the last quarter. LSV Asset Management acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $1,826,000. Raiffeisen Bank International AG increased its stake in shares of BioMarin Pharmaceutical by 7.6% during the 2nd quarter. Raiffeisen Bank International AG now owns 23,480 shares of the biotechnology company's stock worth $1,272,000 after purchasing an additional 1,651 shares in the last quarter. Finally, Persistent Asset Partners Ltd raised its position in shares of BioMarin Pharmaceutical by 266.3% during the 2nd quarter. Persistent Asset Partners Ltd now owns 44,264 shares of the biotechnology company's stock worth $2,433,000 after purchasing an additional 32,181 shares during the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wolfe Research reiterated an "outperform" rating on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. UBS Group increased their price objective on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their price objective on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Stifel Nicolaus restated a "hold" rating and issued a $61.00 target price (down from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Finally, Tudor Pickering set a $88.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, November 3rd. Sixteen analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $89.91.

• 3 Oversold Stocks with Big RSI Rebound Potential

Read Our Latest Research Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Stock Down 0.2%

BMRN opened at $52.48 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.60. The stock has a market capitalization of $10.08 billion, a price-to-earnings ratio of 19.73, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. The business has a 50-day moving average of $53.64 and a two-hundred day moving average of $56.31. BioMarin Pharmaceutical Inc. has a 12 month low of $50.76 and a 12 month high of $73.51.

• Are Gene Therapy Stocks The Market's Next Big Winners?

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The company had revenue of $776.13 million for the quarter, compared to analysts' expectations of $782.42 million. During the same quarter in the previous year, the company earned $0.91 earnings per share. The company's revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

• Five stocks we like better than BioMarin Pharmaceutical
• What does consumer price index measure?
• Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
• Ride Out The Recession With These Dividend Kings
• Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
• Financial Services Stocks Investing
• Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?

Before you consider BioMarin Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.

While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here